These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26719386)

  • 1. T-Cell Therapy Has Lasting Effects.
    Cancer Discov; 2016 Feb; 6(2):113. PubMed ID: 26719386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR T-cells merge into the fast lane of cancer care.
    Frey NV; Porter DL
    Am J Hematol; 2016 Jan; 91(1):146-50. PubMed ID: 26574400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD22 CAR Therapy Leads to ALL Remissions.
    Cancer Discov; 2017 Feb; 7(2):120. PubMed ID: 28069570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in CAR T-cell therapy for chronic lymphocytic leukemia.
    Porter DL
    Clin Adv Hematol Oncol; 2018 Feb; 16(2):118-120. PubMed ID: 29741512
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
    Hill JA; Li D; Hay KA; Green ML; Cherian S; Chen X; Riddell SR; Maloney DG; Boeckh M; Turtle CJ
    Blood; 2018 Jan; 131(1):121-130. PubMed ID: 29038338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia.
    Advani A
    Best Pract Res Clin Haematol; 2015; 28(2-3):116-23. PubMed ID: 26590768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are chimeric antigen receptor T cells ready for prime time?
    Brentjens RJ
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):17-9. PubMed ID: 27057662
    [No Abstract]   [Full Text] [Related]  

  • 10. Chimeric antigen receptor T cells for ALL.
    Amrolia PJ; Pule M
    Lancet; 2015 Feb; 385(9967):488-90. PubMed ID: 25319502
    [No Abstract]   [Full Text] [Related]  

  • 11. CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.
    Lorentzen CL; Straten PT
    Scand J Immunol; 2015 Oct; 82(4):307-19. PubMed ID: 26099639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered cell therapy for cancer gets thumbs up from FDA advisers.
    Ledford H
    Nature; 2017 Jul; 547(7663):270. PubMed ID: 28726836
    [No Abstract]   [Full Text] [Related]  

  • 13. Advances in T-cell therapy for ALL.
    Grupp SA
    Best Pract Res Clin Haematol; 2014; 27(3-4):222-8. PubMed ID: 25455270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In conversation with a pharmacist: management of CAR T-cell treatment.
    Dangi-Garimella S
    Am J Manag Care; 2017 Oct; 23(12 Spec No.):SP480-SP481. PubMed ID: 29087666
    [No Abstract]   [Full Text] [Related]  

  • 15. The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies.
    Fedorov VD; Upadhyay VA; Fathi AT
    Curr Hematol Malig Rep; 2016 Jun; 11(3):165-74. PubMed ID: 26939921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor T-cell therapy for ALL.
    Maude SL; Shpall EJ; Grupp SA
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):559-64. PubMed ID: 25696911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR T-Cell Therapy: Pediatric Patients With Relapsed and Refractory Acute Lymphoblastic Leukemia
.
    Callahan C; Baniewicz D; Ely B
    Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):22-28. PubMed ID: 28315553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective.
    Shah N; Rezvani K; Hosing C; Kebriaei P; Wierda W; Cooper L; Shpall E
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl(Suppl):S18-22. PubMed ID: 25486950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.
    Teachey DT; Lacey SF; Shaw PA; Melenhorst JJ; Maude SL; Frey N; Pequignot E; Gonzalez VE; Chen F; Finklestein J; Barrett DM; Weiss SL; Fitzgerald JC; Berg RA; Aplenc R; Callahan C; Rheingold SR; Zheng Z; Rose-John S; White JC; Nazimuddin F; Wertheim G; Levine BL; June CH; Porter DL; Grupp SA
    Cancer Discov; 2016 Jun; 6(6):664-79. PubMed ID: 27076371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.
    Chen R; Song XT; Chen B
    Discov Med; 2015 Oct; 20(110):185-90. PubMed ID: 26562471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.